[Tofacitinib]

Dtsch Med Wochenschr. 2014 May;139(19):1003-8. doi: 10.1055/s-0034-1369986. Epub 2014 Apr 29.
[Article in German]

Abstract

Tofacitinib is the first Janus kinase inhibitor which was approved for the therapy of rheumatoid arthritis in the USA. Several phase III studies proved the efficacy of Tofacitinib as monotherapy or in combination with established medication. This article discusses the therapeutic potential of this new pharmacological approach and the current data on efficacy and safety of Tofacitinib therapy with special emphasis on a prospective approval in the EU.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Administration, Oral
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Clinical Trials, Phase III as Topic
  • Drug Approval
  • Europe
  • Humans
  • Piperidines / adverse effects
  • Piperidines / pharmacokinetics
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / therapeutic use*
  • Pyrroles / adverse effects
  • Pyrroles / pharmacokinetics
  • Pyrroles / therapeutic use*
  • Treatment Outcome

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • tofacitinib